Literature DB >> 25545208

Monoclonal antibodies specific for human IgM Fc receptor inhibit ligand-binding activity.

Yoshiki Kubagawa1, Kazuhito Honjo, Dong-Won Kang, Hiromi Kubagawa.   

Abstract

A panel of six different murine hybridoma clones secreting IgG monoclonal antibodies (MAbs) specific for the human IgM Fc receptor (FcμR) was generated. All MAbs specifically precipitated a major protein of ∼60 kDa from membrane lysates of FcμR-bearing, but not FcμR-negative, cells as did IgM-ligands. Pre-incubation of membrane lysate of FcμR-bearing cells with these MAbs completely removed the ∼60 kDa IgM-reactive protein. By using recombinant human/mouse chimeric FcμR proteins, the epitope recognized by HM7 and HM10 MAbs was mapped to the Ig-like domain of human FcμR, whereas the other MAbs recognized the stalk region. Pre-incubation of FcμR(+) cells with the Ig-like domain-specific MAbs, but not with others, markedly inhibited subsequent IgM-ligand binding. A similar, but much weaker, inhibition was also observed when the incubation order was reversed. When FcμR(+) cells were simultaneously incubated with both IgM-ligands and MAbs, HM7 MAb efficiently competed with IgM for FcμR binding. Unlike control Jurkat cells, FcμR-bearing cells were resistant to apoptosis induced by agonistic IgM anti-Fas MAb (CH11); however, addition of the HM7 MAb inhibited the interaction of the Fc portion of CH11 MAb with FcμR, thereby promoting apoptosis of FcμR-bearing Jurkat cells. The variable regions of the HM7 MAb were composed of Ighv14-3, Ighd1-2, and Ighj2 for the γ2b heavy chain and Igk3-4 and Igkj2 for the κ light chain. These findings suggest that HM7 MAb efficiently blocks the ligand-binding activity of FcμR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25545208      PMCID: PMC4278172          DOI: 10.1089/mab.2014.0053

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  28 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

Review 2.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  IgM binding protein expressed by activated B cells.

Authors:  S K Sanders; H Kubagawa; T Suzuki; J L Butler; M D Cooper
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

4.  Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia.

Authors:  Fu Jun Li; Yoshiki Kubagawa; Matthew K McCollum; Landon Wilson; Tomoko Motohashi; Luigi F Bertoli; James C Barton; Stephen Barnes; Randall S Davis; Hiromi Kubagawa
Journal:  Blood       Date:  2011-09-09       Impact factor: 22.113

5.  TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.

Authors:  Bérengère Vire; Alexandre David; Adrian Wiestner
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

Review 6.  Monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

7.  Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.

Authors:  Christian Philipp Pallasch; Alexandra Schulz; Nadine Kutsch; Janine Schwamb; Susanne Hagist; Hamid Kashkar; Alfred Ultsch; Claudia Wickenhauser; Michael Hallek; Clemens-Martin Wendtner
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

8.  Identification of TOSO/FAIM3 as an Fc receptor for IgM.

Authors:  Hideaki Shima; Hiroyuki Takatsu; Shinji Fukuda; Masumi Ohmae; Koji Hase; Hiromi Kubagawa; Ji-Yang Wang; Hiroshi Ohno
Journal:  Int Immunol       Date:  2009-12-30       Impact factor: 4.823

9.  Identity of the elusive IgM Fc receptor (FcmuR) in humans.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; G Larry Gartland; Luigi F Bertoli; Hiromi Mori; Hiroyuki Takatsu; Toshio Kitamura; Hiroshi Ohno; Ji-Yang Wang
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

10.  Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice.

Authors:  Zhiyan Liang; Chun Xie; Cui Chen; Desi Kreska; Kelvin Hsu; Liunan Li; Xin J Zhou; Chandra Mohan
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

View more
  2 in total

1.  Soluble Fc Receptor for IgM in Sera From Subsets of Patients With Chronic Lymphocytic Leukemia as Determined by a New Mouse Monoclonal Antibody.

Authors:  Pedram Mahmoudi Aliabadi; Ruth Teuber; Peter K Jani; Landon Wilson; Philipp Enghard; Stephen Barnes; Nicholas Chiorazzi; Andreas Radbruch; Fritz Melchers; Hiromi Kubagawa
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

2.  Identification of Amino Acid Residues in Human IgM Fc Receptor (FcµR) Critical for IgM Binding.

Authors:  Christopher M Skopnik; Khlowd Al-Qaisi; Rosaleen A Calvert; Philipp Enghard; Andreas Radbruch; Brian J Sutton; Hiromi Kubagawa
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.